302 related articles for article (PubMed ID: 16728277)
21. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells.
Yokoi H; Myers A; Matsumoto K; Crocker PR; Saito H; Bochner BS
Allergy; 2006 Jun; 61(6):769-76. PubMed ID: 16677248
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
23. Human-specific expression of Siglec-6 in the placenta.
Brinkman-Van der Linden EC; Hurtado-Ziola N; Hayakawa T; Wiggleton L; Benirschke K; Varki A; Varki N
Glycobiology; 2007 Sep; 17(9):922-31. PubMed ID: 17580316
[TBL] [Abstract][Full Text] [Related]
24. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Cao H; Crocker PR
Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
[TBL] [Abstract][Full Text] [Related]
25. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
26. A uniquely human consequence of domain-specific functional adaptation in a sialic acid-binding receptor.
Sonnenburg JL; Altheide TK; Varki A
Glycobiology; 2004 Apr; 14(4):339-46. PubMed ID: 14693915
[TBL] [Abstract][Full Text] [Related]
27. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
[TBL] [Abstract][Full Text] [Related]
28. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Uckun FM; Ramakrishnan S; Houston LL
J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
[TBL] [Abstract][Full Text] [Related]
29. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.
Kalina T; Vaskova M; Mejstrikova E; Madzo J; Trka J; Stary J; Hrusak O
BMC Cancer; 2005 Apr; 5():38. PubMed ID: 15826304
[TBL] [Abstract][Full Text] [Related]
30. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
31. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
[TBL] [Abstract][Full Text] [Related]
32. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage.
Hoyer JD; Grogg KL; Hanson CA; Gamez JD; Dogan A
Am J Clin Pathol; 2008 Feb; 129(2):316-23. PubMed ID: 18208813
[TBL] [Abstract][Full Text] [Related]
33. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody therapy in acute myeloid leukemia.
Feldman EJ
Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
[TBL] [Abstract][Full Text] [Related]
35. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia.
Tamura H; Dan K; Tamada K; Nakamura K; Shioi Y; Hyodo H; Wang SD; Dong H; Chen L; Ogata K
Clin Cancer Res; 2005 Aug; 11(16):5708-17. PubMed ID: 16115907
[TBL] [Abstract][Full Text] [Related]
36. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9.
Miyazaki K; Sakuma K; Kawamura YI; Izawa M; Ohmori K; Mitsuki M; Yamaji T; Hashimoto Y; Suzuki A; Saito Y; Dohi T; Kannagi R
J Immunol; 2012 May; 188(9):4690-700. PubMed ID: 22467657
[TBL] [Abstract][Full Text] [Related]
37. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
38. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells.
Pérez-Oliva AB; Martínez-Esparza M; Vicente-Fernández JJ; Corral-San Miguel R; García-Peñarrubia P; Hernández-Caselles T
Glycobiology; 2011 Jun; 21(6):757-70. PubMed ID: 21278227
[TBL] [Abstract][Full Text] [Related]
39. Siglecs in innate immunity.
Crocker PR
Curr Opin Pharmacol; 2005 Aug; 5(4):431-7. PubMed ID: 15955740
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
